Gilead Sciences stock trades steady as HIV and oncology pipeline supports long term growth

Gilead Sciences stock reflects a balance between mature antiviral franchises and investment in oncology and HIV prevention, with recent results showing higher revenue and disciplined R&D spending.

Gilead Sciences Inc. (ISIN US3755581036) stock represents a large-cap biotechnology name with a mature antiviral franchise and a growing focus on oncology and HIV prevention. In its latest reported full year 2024 results, according to the company, Gilead generated total revenue of about $28 billion, reflecting an increase from roughly $27 billion in 2023 and underscoring the stability of its core HIV and antiviral businesses. The company is listed on Nasdaq and its shares form part of major US biotech indices, which keeps Gilead Sciences stock closely watched among healthcare investors globally.

Revenue around $28 billion in 2024

In the 2024 reporting period, Gilead disclosed that total product sales were near the $28 billion mark, up from approximately $27 billion in 2023, highlighting mid-single-digit year over year growth driven largely by HIV therapies and oncology contributions. HIV product revenue, anchored by branded regimens such as Biktarvy and Descovy, accounted for the largest portion of sales and showed a modest increase versus 2023 on the back of continued uptake in both treatment and prevention segments. By contrast, Veklury, Gilead's COVID-19 antiviral, declined versus the prior year as pandemic-related demand waned, but this was offset by steady HIV sales and expanding oncology revenues from cell therapy and targeted treatments.

From a profitability perspective, Gilead reported that its 2024 net income remained in the multi-billion dollar range, with operating margin supported by high-volume HIV products and disciplined expense management. The company continued to invest heavily in research and development, allocating a significant proportion of its revenue to R&D spending to advance its pipeline in virology, oncology, and inflammation. This spending level, while substantial in absolute terms, was consistent with prior years and reinforced the company's strategy of maintaining leadership in HIV while building a diversified oncology portfolio that can offset potential future declines in legacy antiviral products.

Oncology and HIV franchises drive mix

Gilead's oncology business, particularly cell therapies for hematologic malignancies and emerging solid tumor indications, continued to grow as an important revenue contributor in 2024 compared with 2023. Oncology product sales, including cell therapy and targeted agents, rose versus the prior year, helping diversify the revenue mix and reducing reliance on HIV and hepatitis C products. The company emphasized that oncology growth was supported by increased patient access, broader reimbursement coverage in key markets, and a growing body of clinical data that supports longer-term use of its therapies. Although oncology still accounts for a smaller share of total revenue than HIV, its faster growth rate provides an important strategic counterbalance for Gilead Sciences stock.

HIV remains the core franchise, with combination therapies designed for once-daily dosing and high barriers to resistance. In 2024, Gilead highlighted sustained global demand for its flagship HIV regimen Biktarvy, which continued to gain share in both treatment-naive and switch patients. The company also pointed to the role of Descovy in pre-exposure prophylaxis, supporting prevention-focused revenue. Compared with 2023, HIV product revenue increased, demonstrating that despite competitive pressure from other antiretroviral regimens, Gilead's portfolio remains central to standard-of-care HIV treatment and prevention in many markets, a fact that underpins investor confidence in Gilead Sciences stock.

Cash generation and capital allocation

Gilead has a long history of strong cash generation, and in 2024 it continued to produce significant operating cash flow from its antiviral franchises. This cash flow supported ongoing dividends to shareholders and occasional share repurchases, signaling management's commitment to returning capital while still investing in growth. The company's balance sheet carries a mix of cash and long-term debt, reflecting past acquisitions in oncology and virology, but leverage remains manageable relative to its earnings and cash flow profile. For investors tracking Gilead Sciences stock, the combination of high-margin HIV products, an expanding oncology portfolio, and disciplined capital allocation remains central to the long-term investment case.

Guidance commentary from management around the 2024 reporting period indicated expectations for relatively stable total revenue in the near term, with HIV and oncology projected to offset declines in COVID-19 related sales. The company reiterated its focus on advancing late-stage candidates in oncology and virology, including combination regimens and novel mechanisms of action that can address resistance and unmet needs. While guidance ranges and specific figures for 2025 may evolve as pipeline milestones are reached, the 2024 comparison versus 2023 already demonstrates Gilead's ability to grow revenue modestly while sustaining profitability.

Product focus on Biktarvy HIV regimen

A key product behind Gilead's HIV franchise is Biktarvy, a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide designed for once-daily dosing in adults living with HIV. Biktarvy has become one of the world's leading HIV treatments, and in 2024 it remained a major revenue driver for Gilead, with sales contributing a substantial portion of the company's HIV revenue and showing an increase compared with 2023. The regimen's efficacy, safety profile, and convenience have supported its broad adoption in both the United States and international markets, and its performance is closely watched because it underpins a meaningful share of the cash flows that support Gilead Sciences stock.

Gilead Sciences stock and market context

Gilead Sciences stock is listed on Nasdaq under the ticker GILD and represents a major constituent of US biotechnology indexes tracked by institutional investors. The company had a market capitalization in the tens of billions of dollars as of the latest reporting period, reflecting its role as a mature but still innovative biopharmaceutical company. While short-term share price movements may respond to clinical-trial updates, patent developments, or broader sector sentiment, the medium-term trajectory for Gilead Sciences stock is anchored in the performance of its HIV and oncology franchises, its ability to manage declines in COVID-19 therapeutics, and the pace of pipeline progress in areas such as long-acting HIV therapies and new oncology indications.

Gilead Sciences stock key data

• Company: Gilead Sciences Inc.
• ISIN: US3755581036
• Ticker: NASDAQ: GILD
• Trading venue: Nasdaq
• Sector / Industry: Health Care / Biotechnology
• Index membership: Major US biotechnology indexes